Myelofibrosis Secondary to PV and ET-Prognostic Model (MYSEC-PM)

ورودی‌های بالینی بیمار

حداقل ۱۸ — حداکثر ۱۲۰ • واحد: years

حداقل ۳ — حداکثر ۲۰ • واحد: g/dL

حداقل ۰ — حداکثر ۱۰۰ • واحد: %

حداقل ۱ — حداکثر ۲۰۰۰ • واحد: ×10⁹/L

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
mysec pm score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Low Risk0–10.99
  • Intermediate-1 Risk11–13.99
  • Intermediate-2 Risk14–15.99
  • High Risk16–50
Direct Clinical Answer

The Myelofibrosis Secondary to PV and ET-Prognostic Model (MYSEC-PM) calculates predicting survival in patients with myelofibrosis secondary to polycythemia vera (PV) and essential thrombocythemia (ET). Key inputs include age years. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. Routine clinical application promotes standardized evidence-based patient management.

Clinical Guidelines & Evidence

Predicts survival in patients with myelofibrosis secondary to polycythemia vera (PV) and essential thrombocythemia (ET). This specialized prognostic model was developed specifically for secondary myelofibrosis, incorporating clinical parameters and molecular genetic information to provide superior risk stratification compared to models designed for primary myelofibrosis.

Clinical Indication

The Myelofibrosis Secondary to PV and ET-Prognostic Model (MYSEC-PM) is indicated for bedside clinical practice to support Predicts survival in patients with myelofibrosis secondary to polycythemia vera (PV) and essential thrombocythemia (ET). This specialized prognostic model was developed specifically for secondary myelofibrosis, incorporating clinical parameters and molecular genetic information to provide superior risk stratification compared to models designed for primary myelofibrosis.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.

Limitations & Contraindications

Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.

Clinical Pearls & Action Plan

Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: The model has been validated in multiple cohorts and is adopted by NCCN and European guidelines.

Formula & Variables:

MYSEC-PM Score = (Age × 0.15) + (Hemoglobin <11 g/dL × 2) + (Circulating blasts ≥3% × 2) + (Platelet count <150 × 1) + (Constitutional symptoms × 1) + (CALR unmutated × 2)

Input Parameters

NameTypeRequiredDescription
age_yearsintegerYesPatient age in years. Age is a continuous variable in MYSEC-PM, contributing 0.15 points per year(years)
hemoglobinfloatYesHemoglobin level in g/dL. Levels <11 g/dL indicate severe anemia and contribute 2 points to risk score(g/dL)
circulating_blastsfloatYesPercentage of circulating blasts in peripheral blood. ≥3% indicates disease progression and contributes 2 points(%)
platelet_countfloatYesPlatelet count in ×10⁹/L. Count <150 indicates thrombocytopenia and contributes 1 point to risk score(×10⁹/L)
constitutional_symptomsstringYesPresence of constitutional symptoms (weight loss >10% in 6 months, night sweats, fever). Indicates systemic disease burden and contributes 1 point
calr_mutation_statusstringYesCALR (Calreticulin) mutation status. Unmutated CALR is associated with poor prognosis and contributes 2 points to risk score

Score Interpretation & Guidance

RangeStageDescription
0–10.99Low RiskLow risk secondary myelofibrosis
11–13.99Intermediate-1 RiskIntermediate-1 risk secondary myelofibrosis
14–15.99Intermediate-2 RiskIntermediate-2 risk secondary myelofibrosis
16–50High RiskHigh risk secondary myelofibrosis

Evidence-Based References (EBM)

  • Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia. 2017;31(12):2726-2731. doi: 10.1038/leu.2017.169.DOI: 10.1038/leu.2017.169
  • Guglielmelli P, Rotunno G, Pacilli A, Rumi E, Rosti V, Delaini F, et al. Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients. Am J Hematol. 2016;91(9):918-22. doi: 10.1002/ajh.24423.DOI: 10.1002/ajh.24423
  • Tefferi A, Guglielmelli P, Lasho TL, Rotunno G, Finke C, Mannarelli C, et al. MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis. J Clin Oncol. 2018;36(17):1769-1770. doi: 10.1200/JCO.2018.78.9867.DOI: 10.1200/JCO.2018.78.9867

Related calculators